Skip to content
Research Article Open access CC BY 4.0

Using miR-125b in the Prediction of Aromatase Inhibitors Resistance in Metastatic Breast Cancer

Ashraf Zedain, Hosney Badrway, Ahmed Refaat, Dina Ismail Abd El Razik, Ahmed Mahran, Abeer Ibrahim

Journal of Cancer and Tumor International · pp. 1–9 · Published 6 Aug 2020

10.9734/jcti/2020/v10i330127

Abstract

Background: Several studies investigated the miRNAs in cancer trying to assess the prognosis or to predict the response to certain treatment .One of these miRNAs are miR 125b , it was suggested by previous results as a good marker for prediction of aromatase inhibitors (AI) response. So, this study was conducted to assess the value using miRNA125b as a predictive factor to AI response. Patients and Methods: A total of 90 patients of postmenopausal HR+ve metastatic breast cancer who attended to medical oncology department outpatient’s clinic in SECI, Assiut university Egypt, from May 2017 to September 2018. Patients presented with metastasis at diagnosis as well as patients who relapsed only after 3 years of adjuvant hormonal treatment with SERM were included. All patients received AI as first line treatment for metastatic, miRNA 125b was isolated from peripheral blood samples and measured by using (q PCR).The response of patients was assessed by RECIST criteria and correlated with its expression levels. Results: Expression of the miR125-b was significantly higher in patients than control p= 0.000. However, no significant difference in its expression between those with single of multiple metastases or even between the site of metastases. We didn’t find also any significant difference in response p=0.648 and survival either PFS p=0.406 or OS p=0.384 between those patients with high expression vs. low expression. Conclusion: Our results suggest that miR125b could be used as a diagnostic marker as it is significantly increased in patients than control. However, we don’t recommend using miR125b as a marker to predict the AI resistance as further studies with large sample size are needed to confirm these results.

Breast cancer miR125b predictive factor aromatase inhibitors.

References (32)

  1. 1 Nonparametric Estimation from Incomplete Observations [DOI]
  2. 2 Nonparametric Estimation from Incomplete Observations [DOI]
  3. 3 New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [DOI]
  4. 4 Circulating microRNAs as stable blood-based markers for cancer detection [DOI]
  5. 5 microRNAs as oncogenes and tumor suppressors [DOI]
  6. 6 Tumour invasion and metastasis initiated by microRNA-10b in breast cancer [DOI]
  7. 7 Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
  8. 8 MicroRNA profiling: approaches and considerations [DOI]
  9. 9 Mechanisms of Endocrine Resistance in Breast Cancer [DOI]
  10. 10 MicroRNAs in Development and Disease [DOI]
  11. 11 Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer [DOI]
  12. 12 Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors [DOI]
  13. 13 Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression [DOI]
  14. 14 Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer [DOI]
  15. 15 Circulating microRNAs in plasma as early detection markers for breast cancer [DOI]
  16. 16 The Dlk1-Gtl2 Locus Preserves LT-HSC Function by Inhibiting the PI3K-mTOR Pathway to Restrict Mitochondrial Metabolism [DOI]
  17. 17 Diverse human extracellular RNAs are widely detected in human plasma [DOI]
  18. 18 Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways [DOI]
  19. 19 A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer [DOI]
  20. 20 miR‐99a directly targets the mTOR signalling pathway in breast cancer side population cells [DOI]
  21. 21 Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer [DOI]
  22. 22 MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer [DOI]
  23. 23 mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels [DOI]
  24. 24 Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft Model [DOI]
  25. 25 Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy [DOI]
  26. 26 Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones [DOI]
  27. 27 Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications [DOI]
  28. 28 Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor [DOI]
  29. 29 Exploring circulating micro‐ RNA in the neoadjuvant treatment of breast cancer [DOI]
  30. 30 Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients [DOI]
  31. 31 Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer [DOI]
  32. 32 Role of micro-RNAs in breast cancer surgery [DOI]

Cited by 3

ASSOCIATION OF miRNA EXPRESSION PATTERN WITH OUTCOME OF LETROZOLE THERAPY IN BREAST CANCER PATIENTS

O. Pridko, T. Borikun, O. Rossylna · Experimental Oncology · 2023

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

30

Page views

0

PDF downloads

4

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.